pemphigoid
Conditions
Interventions
Pemphigus vulgaris patients mild group:None
Healthy control group:None
Pemphigus vulgaris patients moderate group:None
Pemphigus vulgaris patients severe group:None
Sponsors
The Second Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for pemphigus vulgaris: confirmed by clinical, skin histopathological examination and/or immunofluorescence examination, meeting the diagnostic criteria for pemphigus vulgaris. 2. Inclusion criteria for the control group: healthy people with no autoimmune history in themselves or their families, and matched with the patient group in age, gender, etc.
Exclusion criteria
Exclusion criteria: 1. Patients who used hormones or immunosuppressants before specimen collection and suffered from other immune diseases; 2. History of active tuberculosis within 1 year prior to screening; 3. Active and uncontrolled viral infection at the time of screening, or bacterial, viral, parasitic or fungal infection with any clinical symptoms requiring treatment; 4. Patients who have a history of mental illness or genetic history of mental illness or have experienced epilepsy and used antipsychotics or sedative drugs; 5. Patients with a history of serious cardiovascular, liver, kidney, digestive tract, nerve, skin and other diseases or malignant tumors; 6. Other skin diseases affecting the evaluation of test results at the time of screening; 7. Patients who received major surgery within 4 weeks before screening; 8. A history of drug use or drug abuse or regular (> 3 times/week) use of sedatives, sleeping pills, tranquilizers and other addictive drugs in the 4 weeks prior to screening; 9. Patients with a history of myocardial infarction, heart failure, unstable angina, or existing life-threatening arrhythmia within 4 weeks of randomization; 10. Blood loss >=400ml within 4 weeks prior to screening (including trauma, blood collection and blood donation); 11. Lactating patients or pregnant patients; 12. Any patients deemed unfit by the investigator to participate in this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-3;IL-4;IL-5;IL-10;IL-13;IL-17;IL-22;IL-31;Peripheral blood chemokine a;Stromal cell derived factor-1a;IL-27;IL-1ß;Serum eosinophilic activating chemokines;IL-17;Chemokine-like factor;Interferon-?;Granulocyte-macrophage colony-stimulating factor;TNF-a;Serum macrophage inflammatory protein;Monocyte chemokine protein;IL-15;IL-17;IL-18;IL-21;IL-22;IL-23; | — |
Countries
China
Contacts
Public ContactJiang Fuqiong
Outcome results
None listed